New York Cancer & Blood Specialists (NYCBS) has launched a new initiative to expand access to cutting-edge treatment options through an enhanced partnership with Paradigm Health, Inc. (Paradigm)
Ridge, NY, October 31, 2024 – New York Cancer & Blood Specialists (NYCBS) has launched a new initiative to expand access to cutting-edge treatment options through an enhanced partnership with Paradigm Health, Inc. (Paradigm). By leveraging Paradigm’s advanced technology platform, NYCBS will streamline its ability to offer, recruit for, and conduct clinical trials across its growing network of 64 locations. This collaboration will increase patient access to innovative therapies and accelerate clinical research efforts, positioning NYCBS at the forefront of cancer care in New York.
“Our mission is to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends,” said Jeff Vacirca, MD, CEO of NYCBS. “Through our partnership with Paradigm, we are making clinical trials as accessible as routine care, ensuring all our patients have the opportunity to participate in innovative, potentially life-saving therapies. By utilizing Paradigm’s technology, we can efficiently source and operationalize trials, further extending access to cutting-edge treatments, particularly in underserved communities.”
NYCBS has a full-service research department and a dedicated team of specialists integrated into the routine clinical workflow. Historically, NYCBS has run over 60 concurrent interventional clinical trials, spanning phases 1 through 4. With Paradigm’s partnership, NYCBS will expand the number of available trials and ensure that more patients can access these opportunities without leaving their communities.
"Our partnership with Paradigm perfectly supports NYCBS’s role as a leader in clinical care and clinical research,” said Ruth Morgan, Chief Research Officer of NYCBS. “By integrating Paradigm's technology and services with our extensive care network and expertise, we're both bringing new trial options to patients and helping advance clinical research. We’re proud to align our commitment to excellence in research with Paradigm's innovative platform, to benefit the diverse communities we serve."
“It’s an honor to support the next chapter in NYCBS’ esteemed history of patient care,” said Kent Thoelke, CEO of Paradigm. “This collaboration will ensure that every NYCBS patient, regardless of their location, has the opportunity to be considered for potentially life-saving therapies. We support NYCBS in their mission to provide world-class, community-based cancer care, and are dedicated to working together in advancing the field of oncology research."
Since its launch in 2023, Paradigm has successfully collaborated with dozens of community-based provider organizations across the U.S. to expand patient access to clinical trials. Their seamless platform gives healthcare providers and trial sponsors an unprecedented opportunity to work together to conduct trials more effectively and bring potentially life-saving therapies to patients faster.
About New York Cancer & Blood Specialists
New York Cancer & Blood Specialists (NYCBS) is a leading oncology practice in the New York Metropolitan area committed to providing world-class, patient-centered affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. NYCBS has more than 30 locations and 35 hospital affiliations throughout Nassau and Suffolk counties, in the Bronx, Manhattan, Queens, Staten Island, Brooklyn and Upstate New York. We offer a multidisciplinary and comprehensive approach to care that utilizes the most advanced imaging, state-of-the-art therapies, cutting-edge clinical trials, on-site pharmacies, and an in-house laboratory with a full range of pathology services. Advocating for and ensuring the health and well-being of our patients is and always will be our top priority. For more information, visit www.nycancer.com.
About Paradigm
Paradigm Health Inc. (“Paradigm”) is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster. For more information, please visit www.paradigm.inc.
Media Contact
Paradigm Communications: Jacquelyn Miller
Email: Jacquelyn.Miller@paradigm.inc
